EFFICACY AND SAFETY THE COMBINATION OF VILDAGLIPTIN AND GLIQUIDON

Diabetes mellitus (DM) type 2 is a real epidemic of modern society and its incidence continues to rise. In diabetes type 2 accounts for 90% of all cases of diabetes in the world. Diabetes type 2 is a progressive disease type, due to the gradual decrease in mass of pancreatic β-cells, which leads to deterioration with time control. Also found in a significant number of patients with diabetes and diabetic nephropathy significantly complicates the possibility of pharmacotherapy of diabetes. Considering complexity of DM type 2 pathophysiology, its pharmacotherapy is often combine and one of rational combinations is the combination of inhibitors dipeptidylpeptidase-4 (DPP-4) – vildagliptin and derivatives of sulphonylurea – gliquidon, at the same time, this combination has potential for the treatment of DM type 2 accompanied by chronic kidney disease (CKD). However, in the known literature there is no data on its pharmacological efficacy and safety. A typical side effect of sulfonylurea derivatives is the risk of hypoglycemia. Gliquidone is recommended as the drug of choice in patients with DM type 2 with an increased risk of hypoglycemia, but unlike of vildagliptin it is not completely devoid of this undesirable effect. In this study, in vivo in the intact rabbits and in rabbits with experimental alloxaninduced diabetes of the 2nd type were studied hypoglycemic effect of this combination and its safety from the point of view of hypoglycemia. The level of insulin and glucose were measured in serum of venous blood in the dynamics on an empty stomach and after oral glucose load. Radioimmunoassay method was used for measuring the concentration of insulin, glucose oxidase method was used for measuring the concentration of glucose. It was found that the joint use of vildagliptin and gliquidon synergism observed for hypoglycemic effect, however, the risk of hypoglycemia is comparable to that at gliquidonmonotherapy